Full-Time

Scientist 1

Analytical Development

Posted on 9/11/2025

Deadline 2/19/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$80k - $120k/yr

+ Commission + Equity

Chicago, IL, USA

In Person

On-site five days a week; occasional domestic/international travel.

Category
Biology & Biotech (2)
,
Required Skills
Minitab
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • A Bachelor of Science degree with 3+ years of method development experience in an industrial pharmaceutical laboratory OR MS / PhD in analytical chemistry with 1+ years of relevant industrial pharmaceutical experience. Alternatively, a Ph.D. with relevant academic research experience may substitute for some industrial experience.
  • An appropriate understanding of method development, method validation, and method transfer principles.
  • Hands-on experience and expertise with HPLC or UHPLC is a must.
  • Demonstrated understanding of modern chromatographic theory, particularly chromatographic methods focused on Peptides, Proteins and Biologics.
  • Familiarity with GMP/GLP environments and understanding of FDA and ICH guidelines is a plus.
  • Ability to work effectively both independently and collaboratively within a team environment.
  • Prior experience with successful regulatory submissions (IND/NDA/BLA) and commercial method support is a plus.
  • Developing study protocols and reports with meticulous attention to record accuracy and completeness.
  • Working knowledge of Microsoft Productivity software (Excel, Word, PowerPoint, etc.) and Agilent OpenLab.
  • Statistical analysis software such as GraphPad Prism, MiniTab, and JMP is a plus.
  • Competencies: Teamwork & CollaborationAttention to Detail, Self-Starter, Analytical skills, Problem Solving, Organizational skills, Adaptability, Professionalism, Strong Written and Verbal Communication skills.
Responsibilities
  • Develop and perform specific and selective chromatographic methods (i.e. HPLC, UHPLC, LCMS) for use in characterizing prototype pharmaceutical formulations. Where applicable, methods should be compatible with mass selective/mass spectroscopic detection.
  • Collaborate with formulation and analytical scientists in the Product Development group to design appropriate stability programs for drug products.
  • Proficiently configure, operate, and maintain analytical instruments including liquid chromatography systems (HPLC), Karl Fischer titrators, and particle size analyzer.
  • Keep current with relevant literature and industry standards as applicable to research areas.
  • Implement analytical procedures according to compendial monographs and standards (USP, EP).
  • Perform the duties as required for reference standard programs, instrument maintenance and calibration, and drug product stability programs
  • Collect, analyze, and interpret analytical instrument data while maintaining detailed laboratory records.
  • Draft Standard Operating Procedures (SOPs) for laboratory equipment operation and maintenance.
  • Manage external contract laboratories for method development, transfer, and QC testing.
  • Assume a lead SME role in analytical chemistry related team roles and responsibilities (internal and external projects).
  • Prepare development reports and contribute to regulatory submissions, including IND and NDA documentation.
  • Adhere to departmental budgets and spending guidelines.
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).

INACTIVE